Canaccord Genuity analyst Sumant Kulkarni downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Buy to Hold with a price target of $132.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE